Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL
April 13th 2022This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.
Dr Roxana Siles: Multispecialty Management of Chronic Cough Maximizes Patient Benefits
April 12th 2022Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the factors that contribute to necessitating multispecialty management of patients with chronic cough.
AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC
April 12th 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Mixed QOL Findings Following Treatment Highlight Need for BC Support Services
April 9th 2022This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.
Medicare Must Address High ART Costs, Investigators Argue
April 4th 2022With more people living with HIV now reaching advanced ages and qualifying for Medicare coverage, this new study investigated HIV-related influences on their health care spending, particularly antiretroviral therapy (ART), compared with a population who does not have HIV.
Morbidity, Mortality Improve in HFrEF With Combo Treatment vs Monotherapy
April 2nd 2022This new analysis of data from the Swedish Heart Failure Registry involved an investigation into the relationship between therapy count and dosing on mortality and morbidity among patients with heart failure with reduced ejection fraction (HFrEF).
AstraZeneca’s Camille Hertzka: Olaparib Could Be Practice Changing
April 1st 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.
Coffee’s Preventive Benefits for CVD, Heart Disease on Display in Study Pair
March 30th 2022Two studies presented at the annual meeting of the American College of Cardiology show the safety and effectiveness of regular coffee consumption in regard to cardiovascular disease and heart disease, as well as mortality.
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
HIIT Shown to Improve Cardiometabolic Risk in Heart Failure
March 24th 2022This study enrolled 80 middle-aged patients with stage A heart failure and evaluated them for improvements in several cardiovascular and metabolic risk factors through high-intensity interval training (HIIT) for 1 year and omega-3 fatty acid supplementation.
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
March 23rd 2022This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Neutral Findings Predominate German Study of CGM Use
March 22nd 2022This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.